Ozempic and Wegovy both contain semaglutide. The brand and form tell you which conditions the prescription is approved to treat. U.S. labeling now includes both weekly injections and daily tablets under both names. Wegovy has weight-management indications. Ozempic treats type 2 diabetes, and its additional approved uses differ between the injection and tablet. If a prescription or pharmacy notice says only “semaglutide,” check the full product name and form before relying on a dose, benefit claim or set of instructions.
What is each Ozempic or Wegovy product approved to treat?
| U.S. product | Approved uses summarized |
|---|---|
| Ozempic injection, weekly | Improves blood sugar in adults with type 2 diabetes alongside diet and exercise. Reduces the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Reduces specific kidney risks and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. |
| Ozempic tablets, daily | Improve blood sugar in adults with type 2 diabetes alongside diet and exercise. Reduce the risk of major cardiovascular events in adults with type 2 diabetes at high risk for those events. |
| Wegovy injection, weekly | Long-term weight management for eligible adults and for adolescents aged 12 and older with obesity. Reduces the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. Treats noncirrhotic MASH in adults with moderate-to-advanced (F2–F3) liver fibrosis under accelerated approval. |
| Wegovy tablets, daily | Long-term weight management for eligible adults. Reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. |
For both forms of Wegovy, adult weight management covers obesity or overweight with at least one weight-related condition. The weight and cardiovascular indications include a reduced-calorie diet and increased physical activity. Major cardiovascular events in these labels include cardiovascular death, nonfatal heart attack or nonfatal stroke. Ozempic injection label · Ozempic and Rybelsus tablet label · Wegovy injection and tablet label
Is the “heart benefit” the same for both brands?
The event definitions are similar, but eligibility differs. Suppose someone with type 2 diabetes hears a friend was prescribed Wegovy to reduce heart risk. They should ask which cardiovascular criteria apply to their proposed product. Ozempic injection’s cardiovascular indication requires established cardiovascular disease in adults with type 2 diabetes. Ozempic tablets’ indication specifies adults with type 2 diabetes at high risk for major cardiovascular events. Wegovy’s indication requires established cardiovascular disease plus obesity or overweight. The term “heart benefit” by itself leaves out the conditions that distinguish all three.
The kidney claim is narrower still. Ozempic injection’s label covers adults who have both type 2 diabetes and chronic kidney disease, and the labeled outcomes are sustained decline in estimated kidney filtration, end-stage kidney disease and cardiovascular death. If your appointment is about kidney protection, ask whether that specific goal is the reason for the prescription. Ozempic injection label, sections 1 and 14
Which one has the clearer case for weight management?
Wegovy is the brand studied and approved for long-term weight management in the populations listed above. The dose options add detail. For example, a U.S. clinician can consider the 7.2 mg weekly Wegovy injection for an adult who has tolerated 2.4 mg for at least four weeks and for whom further weight reduction is clinically indicated. The 7.2 mg option is an adult weight-management dose. It doesn’t apply to adolescents or to the MASH indication. Wegovy label, section 2.2
If you see a weight-loss percentage for “semaglutide,” check the trial population, product, dose and duration before using it to set expectations. Weight change in people taking Ozempic for diabetes and weight change in people in an obesity trial can both be real without answering which prescription you need. A tablet dose also cannot be compared directly with an injection by looking at the number of milligrams.
What should you do if the pharmacy offers a different form?
Ask the pharmacy to reconcile the full name, form, dose per use and schedule with the prescriber before taking it. These details matter even when the brand stays the same. A refill request for “Ozempic” could refer to a weekly injection or a daily tablet. An offer of Wegovy tablets for an adolescent prescribed Wegovy injection raises an additional question about the approved use, because the tablet weight indication is for adults.
Once the pharmacy confirms the actual prescription, ask for its instructions and check what your plan covers for that product and diagnosis. Use the oral Wegovy instructions for the Wegovy tablet routine. The GLP-1 pill versus injection comparison covers the wider choice of route.
If you have an old supply of one brand, tell the prescriber what you have and when you last took it. Wegovy’s label advises against using it together with other medicines containing semaglutide or other GLP-1 receptor agonists. Have the treatment team confirm which product you’ll use and when to take it. Wegovy label, limitations of use

About the author
Maya Lee
Glowise Senior GLP-1 Content Editor
Maya Lee is a Glowise Health Content Editor. Her guides turn product records, authoritative sources, and everyday organization questions into clear, practical GLP-1 information.
She helps readers ask better questions and keep the details relevant to a care conversation together.
See more Glowise on Google
Add Glowise as a preferred source to find our GLP-1 guides more easily in Google Search.



